"I don't know how much of an increase in eGFR there was but JNJ's Canagliflozin was the first new treatment for CKD to be approved by the FDA in decades. An interesting article, and the drug like ours, seems to have a synergy with SGLT2's"

Canagliflozin/Invokana is an SGLT2 inhibitor, so it can't have synergy with itself! In the CREDENCE trial it only slowed the decline in eGFR; it did not raise it. 

BDAZ